Resting-state functional connectivity of the sensorimotor network in medication-naïve Chinese children with ADHD: cross-sectional associations with hyperactivity/impulsivity and executive function

BackgroundAttention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder, often—but not always—characterized by inattention, hyperactivity/impulsivity, and deficits in executive functions (EFs); some individuals may also exhibit sensorimotor dysfunction. While SMN dysfunction has been implicated in ADHD, the patterns of SMN functional connectivity (FC) and their relationships with clinical symptoms and EFs remain inconsistent, partly due to methodological heterogeneity.MethodsThe study included 62 medication-naïve patients with ADHD (aged 6–15 years) and 46 healthy controls matched for age, sex, and IQ. Clinical symptoms and EFs were assessed using CPRS, IVA-CPT, and Stroop tests. Resting-state fMRI data were acquired, and ROIs within SMN, SN, DMN, and FPN were selected from the Dosenbach atlas. FC was analyzed using Network-Based Statistics (NBS). Partial correlations explored FC–behavior relationships in the ADHD group, controlling for age, sex, and IQ.ResultsThe ADHD group showed significantly higher CPRS hyperactivity/impulsivity scores and poorer IVA-CPT and Stroop performance. Compared to controls, ADHD showed increased FC within SMN (right posterior insula to left precentral gyrus/parietal lobe), between SMN–DMN (precentral gyrus, dorsal frontal cortex, temporal lobe, angular gyrus, posterior cingulate cortex, and precuneus), and SMN–SN (middle insula, superior parietal lobule, superior temporal gyrus, basal ganglia, and fusiform gyrus). Enhanced intra-SMN FC was negatively correlated with impulsivity/hyperactivity and hyperactivity index scores. Enhanced SMN–DMN FC was negatively correlated with hyperactivity symptoms and positively correlated with control quotients in IVA-CPT. Enhanced SMN–SN FC was negatively correlated with Stroop correct responses and positively correlated with omission errors.ConclusionsIn this medication-naïve pediatric sample, distinct SMN connectivity patterns differentially related to ADHD symptoms and executive function. However, given the cross-sectional design and modest sample size, these associations cannot establish causality; they require replication in longitudinal studies and larger cohorts to clarify whether they reflect developmental variation, neurobiological subtypes, or epiphenomena.
<![CDATA[FDA clears Simtriyo, a first-in-class nonstimulant triple reuptake inhibitor for ADHD, offering new symptom and executive-function gains.]]>

Clinical Outcomes and Predictors of Improvement With Virtual Behavioral Health Care for Gambling Disorder: Retrospective Cohort Study

<strong>Background:</strong> Gambling disorder is associated with substantial psychiatric and functional burden, yet few individuals receive treatment. Limited real-world evidence exists evaluating outcomes of virtually delivered behavioral health care for gambling disorder, particularly among clinically complex patients. <strong>Objective:</strong> The purpose of this study was to evaluate gambling symptom severity outcomes among adults with gambling disorder receiving care from Birches Health. We aimed to (1) characterize the clinical profile of adults seeking treatment for gambling disorder; (2) quantify changes in gambling symptom severity over the initial 12 weeks of treatment and examine whether baseline clinical complexity, such as gambling symptom severity, depression severity, and psychiatric comorbidities, was associated with differences in gambling symptom severity improvement over time; and (3) estimate the timing and likelihood of achieving clinically meaningful improvement in gambling symptom severity. <strong>Methods:</strong> This retrospective cohort study included 1305 adults receiving virtual behavioral health treatment for gambling disorder through Birches Health between June 2024 and April 2026. Gambling symptom severity was assessed using the Gambling Symptom Assessment Scale (G-SAS) weekly. Linear mixed-effects models evaluated changes in gambling symptom severity over 12 weeks and associations with baseline clinical characteristics. Clinically meaningful improvement was defined as a reduction of 4 or more points in the G-SAS score. <strong>Results:</strong> Participants had a mean age of 41.5 (SD 13.1) years, 65.2% (851/1305) were male, and baseline gambling symptom severity was moderate (mean G-SAS score 20.5, SD 11.83). Over half (730/1305, 56%) of participants presented with at least one psychiatric comorbidity, most commonly anxiety disorder (351/1305, 26.9%) and depressive disorder (276/1305, 21.1%). Gambling symptom severity declined significantly over the first 12 weeks of treatment, with G-SAS scores decreasing by approximately 0.099 points per day (<i>P</i>&lt;.001), corresponding to an estimated 8.3-point reduction over 12 weeks. Higher baseline depressive symptom severity was associated with faster improvement in gambling symptoms (<i>P</i>=.01), whereas depressive disorder (<i>P</i>=.03) and attention-deficit/hyperactivity disorder (<i>P</i>=.008) diagnoses were associated with slower improvement trajectories. Among patients with routine follow-up assessments recorded during the initial 12 weeks of treatment (1071/1305, 82.1%), 71.7% (935/1305) achieved clinically meaningful improvement in gambling symptom severity, with a median time to improvement of 14 days. <strong>Conclusions:</strong> A clinically complex population of adults receiving care through a national virtual behavioral health care provider demonstrated rapid and clinically meaningful reductions in gambling symptom severity. These findings highlight the potential of specialized virtual care models to expand access to gambling treatment and support symptom improvement in routine care settings. Future research should evaluate longer-term recovery trajectories and identify factors associated with sustained improvement and ongoing engagement in care.

Vagus nerve–driven microbiota homeostasis: a promising integrative add-on therapy for neurodevelopmental disorders

Over the past two decades, the conceptualization of neurodevelopmental disorders (NDDs) has undergone a profound transformation, shifting from a primarily brain-centric framework toward a systems-level perspective that integrates peripheral physiological processes. Among these, the gut microbiota has emerged as a critical determinant of neurodevelopmental trajectories. Through its involvement in immune modulation, metabolic signaling, and neural communication, the microbiota–gut–brain axis (MGBA) exerts a pervasive influence on brain maturation and function. A growing body of evidence indicates that early-life disruptions of microbiota composition—commonly referred to as dysbiosis—are associated with an increased risk of NDDs, including autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and epilepsy. These disruptions are frequently driven by environmental exposures such as antibiotic use, cesarean delivery, dietary patterns, and psychosocial stress. Despite the expanding recognition of these associations, current therapeutic strategies aimed at restoring microbiota balance, including probiotics and fecal microbiota transplantation, have yielded inconsistent and often transient results. In this context, Vagus Nerve Stimulation (VNS), particularly in its non-invasive forms (nVNS), has emerged as a promising approach capable of modulating environmental exposures through the host-centered regulatory mechanisms of the MGBA. By influencing autonomic tone, activating the cholinergic anti-inflammatory pathway, and modulating neurotransmitter systems, nVNS may restore microbiota homeostasis while simultaneously improving neurodevelopmental outcomes. This article provides a comprehensive and integrative review of the mechanistic, preclinical, and clinical evidence supporting the role of nVNS as a microbiota-modulating intervention. We further discuss its potential as a safe, cost-effective and promising therapeutic strategy for neurodevelopmental disorders, with a particular emphasis on pediatric populations.

Diagnostic Discrimination of BOKE STARS, a Bimodal Continuous Performance Test, for Attention-Deficit/Hyperactivity Disorder Assessment in Chinese Children: Single-Center Case-Control Study

Background: Attention-deficit/hyperactivity disorder (ADHD) affects 6.3% of Chinese children, but only 10% are diagnosed, as diagnosis is hindered by low awareness and lack of culturally adapted, objective tools. Existing continuous performance tests are unimodal and lack validity. Objective: This study aimed to conduct an initial evaluation of the diagnostic discrimination of BOKE STARS (Sustained Task and Attention Response Screening), a culturally adapted bimodal continuous performance test, for distinguishing children with ADHD from typically developing children in a Chinese clinical setting. Methods: In this prospective, single-center diagnostic accuracy study with a case-control design, 100 children aged 6 to 12 years (n=50 with ADHD and n=50 controls) were recruited at Xinhua Hospital between January and May 2024. Parents completed the Swanson, Nolan, and Pelham Rating Scale–fourth version (SNAP-IV), and children completed the BOKE STARS assessment on a tablet device under standardized conditions. Group comparisons were conducted using independent-sample 2-tailed tests or Mann-Whitney tests, as appropriate. Receiver operating characteristic (ROC) curve analysis was performed in the full case-control sample to assess diagnostic discrimination. Sensitivity and specificity were reported descriptively across ROC-derived cutoffs; these cutoffs were not interpreted as clinically validated diagnostic thresholds. Secondary exploratory analyses included comparisons among ADHD subtypes and correlations between BOKE STARS indices and parent-reported SNAP-IV symptom severity scores. Results: Compared with controls, children with ADHD performed significantly worse on all major BOKE STARS indices, including errors of omission, errors of commission, reaction time, reaction time variability (RTV), discrimination prime, and total score. In the full case-control sample, the total score showed the strongest diagnostic discrimination (area under the ROC curve [AUC] 0.962, 95% CI 0.931-0.992), followed by RTV (AUC 0.919, 95% CI 0.867-0.971), errors of omission (AUC 0.884, 95% CI 0.818-0.950), and discrimination prime (AUC 0.819, 95% CI 0.737-0.900). Errors of commission (AUC 0.689, 95% CI 0.585-0.792) and reaction time (AUC 0.634, 95% CI 0.524-0.743) showed comparatively weaker discrimination. No significant differences were observed among ADHD subtypes. Several BOKE STARS indices were modestly correlated with SNAP-IV inattention and hyperactivity or impulsivity scores. Conclusions: BOKE STARS showed promising preliminary diagnostic discrimination for identifying Chinese children with ADHD in this case-control sample, with the total score and RTV showing the strongest discriminatory performance. However, because the case-control design artificially fixed the ratio of ADHD cases to controls, diagnostic performance estimates and exploratory cutoffs should be interpreted cautiously and should not be considered representative of real-world clinical diagnostic performance. BOKE STARS may serve as an adjunctive assessment tool to complement clinical interviews and caregiver-reported rating scales, but further external validation in larger and clinically heterogeneous populations is required before broader clinical implementation.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/a352c65e649b80c4b66c3ed01598115e" />

ADHD, Gut Problems and Synbiotic

Conditions: ADHD; Gastrointestinal; Emotion Regulation Abilities

Interventions: Dietary Supplement: Synbiotic Cap Gut-Brain; Other: Placebo

Sponsors: Super Synbiotics AB

Not yet recruiting

Home Play-based Intervention for Parents and Infants

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD); Autism Spectrum Disorder; Premature Birth; Global Developmental Delay

Interventions: Behavioral: SPRINT Intervention; Other: Waitlist Protocol

Sponsors: Nanyang Technological University; Agency for Science, Technology and Research (A*STAR); KK Women’s and Children’s Hospital; Institute for Human Development and Potential (IHDP), Singapore

Not yet recruiting